Results 241 to 250 of about 6,459 (257)

Tirzepatide attenuates lipopolysaccharide-induced left ventricular remodeling and dysfunction by inhibiting the TLR4/NF-kB/NLRP3 pathway

International Immunopharmacology, 2023
Wei Shuai
exaly  

Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial

Lancet, The, 2021
Bernhard Ludvik, Francesco Giorgino, Esteban Jódar   +2 more
exaly  

Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison

Diabetes, Obesity and Metabolism, 2023
Carel W Le Roux, Raleigh E Malik, Ana Hickey   +2 more
exaly  

Adverse Events Related to Tirzepatide

Journal of the Endocrine Society, 2023
Rahul Mishra, Rishi Raj, Ghada Elshimy   +2 more
exaly  

Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis

Diabetologia, 2022
Thomas Karagiannis, Ioannis Avgerinos, Aris Liakos   +2 more
exaly  

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

Lancet, The, 2021
Julio Rosenstock, Carol H Wysham, Juan P Frías   +2 more
exaly  

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Lancet, The, 2021
Stefano Del Prato, Steven E Kahn, Imre Pavo   +2 more
exaly  

Tirzepatide Once Weekly for the Treatment of Obesity

New England Journal of Medicine, 2022
Ania M Jastreboff, Louis J Aronne, Nadia N Ahmad   +2 more
exaly  

Beyond glycemia: Comparing tirzepatide to GLP-1 analogues

Reviews in Endocrine and Metabolic Disorders, 2023
John Andraos, Shawn R Smith
exaly  

Relationship between body weight change and glycaemic control with tirzepatide treatment in people with type 2 diabetes: A post hoc assessment of the SURPASS clinical trial programme

Diabetes, Obesity and Metabolism, 2023
Francesco Giorgino, , Vivian T Thieu
exaly